- A comprehensive review in Frontiers in Neurology assessed 180 studies on the neurological sequelae of Long COVID. “Our analysis suggests that vascular dysfunction, neuroinflammation, and gut-brain axis disruption create self-sustaining feedback loops that maintain chronic symptoms,” the authors wrote. They concluded that Long COVID may be “shifting the landscape of psychiatric and neurological health worldwide.”
- Invivyd, Inc. announced positive data from its Phase 1/2 trial of the novel monoclonal antibody (mAb), VYD2311. The antibody is designed as an alternative to COVID-19 vaccination that would offer better safety and durability against different variants. Next steps for the mAb drug include long-term follow-up of the 40 participants in the current trial and additional, larger studies.
- A new COVID-19 nasal vaccine funded by Project NextGen is entering clinical trials this spring. The phase 1 trial will enroll 80 participants in four different cohorts, testing the vaccine in low and high doses to determine its safety and efficacy. Last year, the vaccine was shown to stop transmission of SARS-CoV-2 in hamsters. “This powerful technology has the potential not only to help control COVID-19 but to reduce the burden of respiratory infections worldwide,” one of the researchers said in a press release.
